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Emerging evidence suggests that undercarboxylated osteocalcin (ucOC) improves 
muscle glucose uptake in rodents. However, whether ucOC can directly increase 
glucose uptake in both glycolytic and oxidative muscles and the possible mechanisms 
of action still need further exploration. We tested the hypothesis that ucOC per  se 
stimulates muscle glucose uptake via extracellular signal-regulated kinase (ERK), 
adenosine monophosphate-activated protein kinase (AMPK), and/or the mechanistic 
target of rapamycin complex 2 (mTORC2)-protein kinase B (AKT)-AKT substrate of 
160 kDa (AS160) signaling cascade. Extensor digitorum longus (EDL) and soleus mus-
cles from male C57BL/6 mice were isolated, divided into halves, and then incubated 
with ucOC with or without the pretreatment of ERK inhibitor U0126. ucOC increased 
muscle glucose uptake in both EDL and soleus. It also enhanced phosphorylation of 
ERK2 (Thr202/Tyr204) and AS160 (Thr642) in both muscle types and increased mTOR 
phosphorylation (Ser2481) in EDL only. ucOC had no significant effect on the phos-
phorylation of AMPKα (Thr172). The inhibition of ucOC-induced ERK phosphorylation 
had limited effect on ucOC-stimulated glucose uptake and AS160 phosphorylation in 
both muscle types, but appeared to inhibit the elevation in AKT phosphorylation only 
in EDL. Taken together, ucOC at the physiological range directly increased glucose 
uptake in both EDL and soleus muscles in mouse. The molecular mechanisms behind 
this ucOC effect on muscle glucose uptake seem to be muscle type-specific, involving 
enhanced phosphorylation of AS160 but limitedly modulated by ERK phosphorylation. 
Our study suggests that, since ucOC increases muscle glucose uptake without insulin, 
it could be considered as a potential agent to improve muscle glucose uptake in insulin 
resistant conditions.
Keywords: undercarboxylated osteocalcin, skeletal muscle, glucose uptake, extracellular signal-regulated 
kinase, adenosine monophosphate-activated protein kinase, mechanistic target of rapamycin complex 2-aKT-
as160 signaling cascade
2Lin et al. ucOC Enhances muscle glucose uptake
Frontiers in Endocrinology | www.frontiersin.org November 2017 | Volume 8 | Article 330
inTrODUcTiOn
The skeleton is an endocrine organ that has been shown, at least 
in mice, to modulate glucose metabolism (1–3). One bone-
specific hormone that plays a role in this energy regulation is 
osteocalcin (OC) (4, 5). Undercarboxylated osteocalcin (ucOC), 
the biologically active form of OC, regulates glucose metabolism 
by targeting the pancreas and perhaps several insulin-sensitive 
organs, including skeletal muscle (6–8). The effect of ucOC on 
skeletal muscle may have important clinical implications for 
whole-body glycemic control as it is the major site for glucose 
disposal and storage (9, 10). It has been reported that ucOC 
increases insulin sensitivity in rodent skeletal muscle (11–15). 
Recent evidence also suggests that ucOC may enhance muscle 
glucose uptake in the absence of insulin. For example, it has been 
shown that 10 ng mL−1 ucOC increases glucose uptake in C2C12 
myotubes, and to a lesser extent in ex vivo soleus muscle which 
mainly relies on oxidative metabolism for energy production, 
but not in ex vivo extensor digitorum longus (EDL) muscle, 
which largely utilize glycolytic metabolism as the energy source 
(15). Similarly, in our previous study, we did not observe any 
effect of ucOC on glucose uptake of non-contracted EDL ex 
vivo (14). However, since GPRC6A, the presumable receptor for 
ucOC, is expressed in both EDL and soleus (14, 15), the regula-
tion on muscle glucose uptake by ucOC in both muscle types is 
still possible. We hypothesize that the limited direct effects of 
ucOC that was previously observed on EDL were likely due to 
the inadequateness of ucOC to access the internal area of intact 
muscle in vitro. Therefore, it is possible that a methodological 
limitation affected the results and improved techniques such as 
the application of muscle strips, which was previously performed 
by Cartee et al. (16) and others (17, 18), need to be introduced.
Furthermore, the potential mechanisms behind ucOC per se 
effect on skeletal muscle glucose uptake are still largely unknown. 
Our previous report exhibited enhanced insulin-stimulated 
glucose uptake and AS160 phosphorylation at Thr642 by ucOC 
treatment in EDL muscle post ex vivo contraction (14). Insulin-
induced phosphorylation of AS160, and subsequent increases in 
glucose uptake, requires fully activated AKT via the activation of 
mechanistic target of rapamycin complex 2 (mTORC2), which 
can be indicated by the phosphorylation of AKT at Ser473 
and the phosphorylation of mTOR at Ser 2481 (19–22). The 
mTORC2-AKT-AS160 signaling cascade can be stimulated 
not only by insulin but also other growth factors and stimuli 
(23–25). Recent findings indicate that ucOC may also be able to 
trigger this signaling pathway. In vascular smooth muscle cells, 
the phosphorylation of AKT was enhanced by the treatment 
of purified bovine OC (26). Furthermore, the phosphoryla-
tion of AKT at Ser473 was elevated following OC treatment in 
descending thoracic aortic strips of ApoE-KO mice (27). In 
addition, the phosphorylation of AKT (Ser473) was increased 
in C2C12 myotubes with ucOC exposure during cell differen-
tiation (13). Nevertheless, the upstream pathway/s that result 
in the phosphorylation of AKT and AS160 by ucOC are still 
unclear. It is possible that two previously identified downstream 
targets of ucOC, extracellular signal-regulated kinase (ERK) and 
adenosine monophosphate-activated protein kinase (AMPK), 
may be involved (28, 29). Indeed, in atrophic rat muscles, lower 
serum ucOC levels were associated with lower phosphorylation 
levels of ERK (Thr202/Tyr204) and AMPK (Thr172), and the 
phosphorylation levels of ERK positively correlated with the 
phosphorylation levels of AKT (S473) in EDL muscle (30). 
In C2C12 myotubes, ucOC-stimulated ERK phosphorylation 
(Thr202/Tyr204) likely contributed to the increase of AKT 
phosphorylation at Ser473 (13). Furthermore, exercise-induced 
p-AMPK (Thr172) was augmented by ucOC injection in mice 
tibialis muscle, which could be responsible for ucOC-enhanced 
exercise-stimulated muscle glucose uptake (15).
Therefore, the aims of this study were to (a) test the hypothesis 
that physiological levels of ucOC per se increases glucose uptake 
in both EDL and soleus muscles and (b) explore the mechanisms 
underlying the effects of ucOC on muscle glucose uptake.
MaTerials anD MeThODs
animals
Eight-week-old male C57BL/6J mice (N = 55) were purchased 
from Animal Resources Centre (WA, Australia). All mice 
were group housed with a 12-h light/12-h dark cycle and fed 
standard laboratory chow [Specialty Feeds mouse food cubes 
(Glen Forrest, WA, Australia) containing 20% protein, 4.8% 
fat, and the rest carbohydrate and fiber] and water ad  libitum 
until 9–12  weeks old. The study was approved by the Animal 
Experimentation Ethics Committee of Victoria University 
(AEC14/009) and conformed to the Australian National Code of 
Practice for the Care and Use of Animals for Scientific Purposes. 
The mice for each group in this study were randomly allocated.
Muscle Dissection
Mice were fasted for 4  h before deep anaesthetization with 
60 mg kg−1 intraperitoneal pentobarbital. Left and right EDL and 
soleus muscles were excised within 30 min of anesthesia. Isolated 
muscles were bathed in carbogenated Krebs–Henseleit buffer 
(KHB) (119  mM NaCl, 4.7  mM KCl, 2.5  mM CaCl2, 1.2  mM 
MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, pH 7.4) and evenly 
divided into halves longitudinally. After muscle dissection, mice 
were euthanized via cervical dislocation under anesthesia.
ucOc stimulation
Muscles were evenly divided longitudinally into halves to 
improve the effusion of ucOC into muscle fiber ex vivo, similar 
to what has been performed in rat muscle in previous studies 
(16–18). The whole ucOC stimulation process is shown in Figure 
S1 in Supplementary Material. In experiments without the ERK 
inhibitor U0126, muscle samples were preincubated in 30°C 
baths containing carbogenated KHB buffer for 1  h. In experi-
ments with U0126 (N = 5), after 30 min preincubation, muscle 
samples were exposed to the ERK inhibitor U0126 (1 µM) (Cell 
Signaling, MA, USA) or dimethyl sulfoxide (DMSO) vehicle 
(Sigma-Aldrich, MO, USA) for 30 min. Then, muscle samples 
were stimulated for 90  min with increasing doses [0  ng  mL−1 
(N = 6), 0.3 ng mL−1 (N = 10), 3 ng mL−1 (N = 10), 10 ng mL−1 
(N  =  14), or 30  ng  mL−1 (N  =  10)] of recombinant ucOC 
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(Bachem, Bubendorf, Switzerland). These doses of ucOC were 
chosen because they are within the physiological range in mice 
(7, 31). In experiments without U0126, muscle halves from the 
same mouse were treated with KHB buffer control or ucOC. In 
experiments with U0126, muscle halves from the same mouse 
were treated with DMSO, DMSO with ucOC, U0126, and U0126 
with ucOC, respectively.
2-Deoxyglucose Uptake Measurement and 
sample homogenization
The method to assess 2-Deoxy-D-glucose (2-DG) uptake has 
been described previously (14). Briefly, after the 90 min ucOC 
treatment, muscles were transferred to chambers containing 
KHB + 0.1% bovine serum albumin (Sigma-Aldrich) + 2 mM 
2-Deoxy-d-[1,2-3H]-glucose (PerkinElmer, MA, USA) and 
16 mM d-[1-14C] mannitol (PerkinElmer) with or without U0126/
Vehicle or ucOC. After 10 min, muscles were rapidly rinsed with 
ice cold KHB buffer, then immediately frozen in liquid nitrogen. 
On the day of sample processing, muscle samples were lysed in 
ice-cold radioimmunoprecipitation assay (RIPA) buffer (60  µL 
RIPA for 1 mg sample) (Cell Signaling) with Inhibitor Cocktail 
(Cell Signaling) and 100  mM dithiothreitol (Sigma-Aldrich) 
using TissueLyser II (QIAGEN, Hilden, Germany) followed 
by gentle rocking at 4°C for 1 h. Half of the lysate was pipetted 
into vials with scintillation cocktail for scintillation counting 
(β-counter) with Tri-Carb 2910TR Liquid Scintillation Analyzer 
(PerkinElmer) and the other half was used in western blotting.
Western Blotting
After muscle samples were homogenized using RIPA buffer, 
protein concentrations in the lysate were determined by Bio-Rad 
Protein Assay (Bio-Rad, CA, USA). Equal amounts of protein 
were subjected to electrophoresis on Criterion stain-free precast 
gels (10%; Bio-Rad) and then transferred electrophoretically 
using Trans-Blot Turbo Transfer System (Bio-Rad) onto a poly-
vinylidene fluoride membrane (Bio-Rad). Then, a stain-free blot 
image was taken using ChemiDoc Imaging System (Bio-Rad) for 
total protein measurement in each sample lane. Immunoblotting 
was performed at optimum conditions for each antibody. 
Bands were identified using ChemiDoc Imaging System, using 
SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo, MA, USA). Band densities of both stain-free blot 
and immunoblotting were measured using Image Lab Software 
(Bio-Rad). Values of immunoblotting bands were normalized 
using total protein values. p-ERK (Thr202/Tyr204), ERK, 
p-AMPKα (Thr172), AMPKα, p-mTOR (Ser2481), mTOR, 
p-AKT (Ser473), AKT, p-AS160 (Thr642), AS160, and p-PKCδ/θ 
(Ser643/676) antibodies were purchased from Cell Signaling.
Two data points for AMPKα phosphorylation assessment 
were excluded due to western blot imaging artifacts. However, 
their exclusion did not alter the statistical outcome, interpreta-
tion, or conclusions of the results.
statistical analysis
Fold-changes for western blotting data were calculated by nor-
malization to control groups within the same animals. 3 ng mL−1 
group and 30 ng mL−1 group were chosen for western blotting 
and correlation analysis as representatives of low and high doses 
of ucOC.
Paired t-tests were used to analyze the effects of ucOC, for 
each individual concentration, on muscle glucose uptake, protein 
phosphorylation, protein abundance, and phospho/total ratio 
compared to paired control samples. This paired comparison was 
used to exclude individual variances.
To analyze the dose–response effects of ucOC on muscle 
glucose uptake, basal glucose uptake data from all groups were 
combined, then one-way ANOVA with Tukey post hoc test was 
applied.
Spearman’s correlation was performed between the variables 
from 30  ng  mL−1 ucOC treatment group. Rule of thumb for 
interpreting the size of a correlation coefficient will be applied 
to measure the strength of correlation between two variables 
(32). According to standard practice thresholds, the r ranges for 
negligible positive, low positive, moderate positive, high positive, 
and very high positive correlations are defined as 0.00 < r < 0.30, 
0.30 ≤ r < 0.50, 0.50 ≤ r < 0.70, 0.70 ≤ r < 0.90, and 0.90 ≤ r ≤ 1.00, 
respectively.
All figures and analyses were performed using GraphPad 6 
(GraphPad Software, La Jolla, CA, USA).
All data are reported as mean ± SEM.
resUlTs
ucOc increased glucose Uptake in both 
eDl and soleus Muscles
Compared with paired controls, muscle glucose uptake was 
significantly higher following the treatment of ucOC at doses 
of 10  ng  mL−1 (P <  0.05) and 30  ng  mL−1 (P <  0.01) in EDL, 
and 0.3 ng mL−1 (P < 0.01) and 30 ng mL−1 (P < 0.01) in soleus 
(Figures  1A,B). When data were analyzed for ucOC dose–
response effects, ucOC significantly enhanced glucose uptake at 
doses equal or larger than 3  ng  mL−1 in EDL and at a dose of 
30 ng mL−1 in soleus (Figures 1C,D; P < 0.05, ANOVA P < 0.01), 
from 2.91 to 4.32 μmol g−1 h−1 and from 3.12 to 4.16 μmol g−1 h−1, 
respectively.
ucOc stimulated the Phosphorylation  
of mTOr, aKT, and as160
In EDL, ucOC treatment at 30  ng  mL−1 significantly increased 
p-mTOR (1.37-fold, P < 0.05, Figure 2A) and p-mTOR/tmTOR 
ratio (1.40-fold, P < 0.05, Figure 2A), and only tended to increase 
p-AKT (1.25-fold, P = 0.074, Figure 2C) but not p-AKT/tAKT 
ratio. Neither of these signaling molecules was affected in the 
soleus (Figures 2B,D). In both EDL and soleus, both p-AS160 
and p-AS160/tAS160 ratio were considerably elevated 1.4-fold 
to 1.8-fold following ucOC treatments at 3  ng  mL−1 (P <  0.05 
and P < 0.05, Figure 2E; P = 0.059 and P = 0.056, Figure 2F) 
and 30 ng mL−1 (P < 0.01 and P < 0.05, Figure 2E; P < 0.01 and 
P < 0.001, Figure 2F). Total AS160 expression was also increased 
by 30 ng mL−1 ucOC in EDL (1.13-fold, P <  0.05, Figure 2E). 
Blots of phosphorylated proteins and total expression of proteins 
are shown as Figure S2 in Supplementary Material.
FigUre 1 | Undercarboxylated osteocalcin (ucOC) effects on and insulin-stimulated glucose uptake in extensor digitorum longus (EDL) and soleus. (a,B) glucose uptake 
of EDL and soleus muscle samples treated with Krebs–Henseleit buffer control and ucOC [0 ng mL−1 (mice N = 6), 0.3 ng mL−1 (mice N = 10), 3 ng mL−1 (mice N = 10), 
10 ng mL−1 (mice N = 14), or 30 ng mL−1 (mice N = 10)] was detected. *P ≤ 0.05 and **P ≤ 0.01 between paired samples (paired t-test); (c,D) glucose uptake of EDL 
and soleus samples was analyzed for dose-response effect of ucOC with combined basal levels. Samples sizes for groups treated with 0, 0.3, 3, 10, or 30 ng mL−1 
ucOC are 56, 10, 10, 14, or 10, respectively. *P ≤ 0.05 and **P ≤ 0.01 in Tukey’s post hoc test (compared with 0 ng mL−1 ucOC samples) of one-way ANOVA analysis.
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ucOc stimulated the Phosphorylation  
of erK but not aMPK
p-ERK2, but not p-ERK2/tERK2 ratio, was increased by the 
treatment of 30 ng mL−1 ucOC (1.14-fold, P < 0.05, Figure 3A) 
in EDL, and by both 3 and 30 ng mL−1 of ucOC in soleus (1.24-
fold and 1.17-fold, P < 0.05 and P < 0.01, Figure 3B). ucOC at 
3 or 30 ng mL−1 had limited effects on AMPKα phosphorylation 
in both EDL and soleus (Figures 3C,D). However, soleus total 
AMPKα levels were increased by the treatment of 30  ng  mL−1 
ucOC (1.30-fold, P < 0.01, Figure 3D). Blots of phosphorylated 
proteins and total expression of proteins are shown as Figure S3 
in Supplementary Material.
Treatment with 30  ng  mL−1 ucOC had limited effects on 
phosphorylated protein kinase C δ/θ (PKCδ/θ) in both EDL and 
soleus muscles (Figure S4 in Supplementary Material).
The Phosphorylation levels of erK2 
correlated with the Phosphorylation 
levels of aKT and as160
p-ERK2 levels were not associated with glucose uptake levels 
(Figures 4A,B) or p-mTOR levels (Figures 4C,D), in either EDL 
or soleus. Higher levels of p-ERK2 were associated with higher 
levels of p-AKT in EDL (P < 0.05, Figure 4E) with a low positive 
correlation (r = 0.48), but not in soleus (Figure 4F). In both EDL 
(P < 0.05, Figure 4G) and soleus (P < 0.001, Figure 4H), higher 
p-ERK2 levels were associated with higher levels of p-AS160, with 
a low positive correlation (r = 0.48) and a high positive correla-
tion (r = 0.85), respectively.
p-AMPKα levels were not associated with glucose uptake or 
any signaling protein phosphorylation levels in either muscle 
type (data not shown).
The Prevention of ucOc-induced erK 
Phosphorylation had limited effect on 
ucOc-stimulated Muscle glucose Uptake
Preincubation with 1  µM U0126 blocked ucOC (30  ng  mL−1)-
induced increases in ERK2 phosphorylation in both EDL and 
soleus (Figures  5A,B). However, the addition of inhibitor did 
not significantly affect ucOC-stimulated muscle glucose uptake 
(Figures 5C,D).
The removal of ucOc-induced erK 
Phosphorylation Prevents  
ucOc-stimulated aKT Phosphorylation  
in eDl, but has limited effect  
on the Phosphorylation of mTOr  
and as160 in Both Muscle Types
U0126 (1 µM) had limited effect on p-mTOR following ucOC 
treatment in either EDL or soleus (Figures  6A,B). However, 
FigUre 2 | Undercarboxylated osteocalcin (ucOC) effects on the phosphorylation of mTOR, AKT, and AS160. The phosphorylation levels, total expression 
levels, and phospho/total ratio levels of mTOR (a,B), AKT (c,D), and AS160 (e,F) of Extensor digitorum longus (EDL) and soleus samples treated with 
Krebs–Henseleit buffer control and ucOC (3 and 30 ng mL−1, N = 10 for each dose) were examined. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 paired samples 
from the same animal (t-test).
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it somewhat prevented the ucOC-mediated AKT activation in 
EDL with a change close to significant observed in phospho-
rylation levels (P =  0.06), but not in soleus (Figures  6C,D). 
Although AS160 phosphorylation shared similar patterns 
of modulation with those of AKT following the treatments, 
ucOC-stimulated AS160 phosphorylation levels were only 
marginally decreased by U0126 addition in both muscle types 
(P > 0.1; Figures 6E,F).
DiscUssiOn
We report that physiological levels of ucOC per  se increased 
muscle glucose uptake ex vivo in both EDL (glycolytic muscle) 
and soleus (oxidative muscle) muscles. Furthermore, ucOC 
increased the phosphorylation of ERK2, mTOR, and AS160 in 
EDL and enhanced the phosphorylation of ERK2 and AS160 
in soleus muscle. It appears that ERK phosphorylation was not 
directly involved in ucOC-stimulated glucose uptake and AS160 
phosphorylation in both muscle types.
We, and others, have previously reported that ucOC had no 
significant effect on resting EDL muscle glucose uptake, indicat-
ing that ucOC per se probably only upregulates muscle glucose 
metabolism in oxidative muscle fibers (14, 15). However, since 
the expression of GPRC6A, which is reported as the plausible 
receptor of ucOC, has been found in both muscle types (14, 15), 
we suggested that the results of these studies were affected by 
a potential methodological limitation that the usage of intact 
whole muscles may prevent adequate ucOC exposure to all 
muscle fibers. In vivo, muscle fibers are closely fed by capillaries 
that penetrate the epimysium and bifurcate throughout the mus-
cle, primarily within perimysium (33). Since both epimysium 
and perimysium belong to robust collagenous connective tissue 
FigUre 3 | Undercarboxylated osteocalcin (ucOC) effects on the phosphorylation of ERK2 and AMPKα. The phosphorylation levels, total expression levels, and 
phospho/total ratio levels of ERK2 (a,B) and AMPKα (c,D) of Extensor digitorum longus (EDL) and soleus samples treated with Krebs–Henseleit buffer control and 
ucOC (3 and 30 ng mL−1, N = 9–10 for each dose) were examined. *P ≤ 0.05 and **P ≤ 0.01 paired samples from the same animal (t-test).
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networks, without the help of blood vessels, ucOC in external 
solution may have limited direct contact with fibers of intact 
muscles during ex vivo incubation. By utilizing the method of 
splitting muscles longitudinally into halves (16–18), in order 
to increase the ucOC saturation during treatment, we report 
that ucOC can increase muscle glucose uptake in the absence of 
insulin in both glycolytic (EDL) and oxidative (soleus) muscles, 
suggesting the effect of ucOC on skeletal muscle glucose uptake 
is likely universal rather than muscle-type specific. It also seems 
that, compared with EDL, higher doses of ucOC are required 
for observing this effect on the glucose uptake of soleus 
(Figures  1C,D). Although there was a significant increase in 
soleus treated with 0.3 ng mL−1 ucOC using paired comparison 
method (Figure 1B), this increase could not be observed when 
data were analyzed using one-way ANOVA. Thus, it was likely 
that this increase was merely resulted from an abnormally low 
control levels in that specific group. Since skeletal muscle is the 
major site of glucose disposal and utilization in the postprandial 
state (9), these findings implicate ucOC as a possible therapeu-
tic agent to improve muscle glucose transport even without 
insulin.
However, it should be noted that even though we introduced 
muscle splits in this study to enhance the interaction between 
ucOC and interior muscle myotubes beneath muscle surface, 
some limitations, which might result in enhanced biological 
variations, such as different ucOC saturation percentages due to 
different muscle dimensions, and different basal glucose uptake 
levels of different individuals, still cannot be ruled out. Therefore, 
future studies should explore the effect of ucOC in primary myo-
tubes from animals and human, to avoid these limitations.
We report that ucOC treatment activated the mTORC2-
AKT-AS160 signaling cascade in skeletal muscle, in a muscle 
type-specific manner. Importantly, ucOC elicited significant 
increases in AS160 phosphorylation (Thr642) despite relatively 
modest increases in AKT phosphorylation (Ser473) (P = 0.074). 
Therefore, ucOC may enhance AS160 phosphorylation via AKT 
independent mechanisms, which may be the major mechanisms 
underlying the ucOC-induced enhancement of glucose uptake 
and AS160 phosphorylation. Indeed, several other signaling 
proteins are also able to increase AS160 phosphorylation, 
including AMPK and conventional/novel (c/n) protein kinase C 
(PKC) (34).
Along with ERK, previous studies have suggested that AMPK 
is a potential downstream target of the ucOC signaling in skel-
etal muscle (13, 15). Our data shows that following 30 ng mL−1 
ucOC treatment, there is a significant increase in phosphoryl-
ated ERK2 (Thr202/Yyr204) in both EDL and soleus muscles. 
However, there was limited change in AMPKα phosphorylation 
at Thr172, a phosphorylation site that has widely been reported 
as an indicator of AMPK activity (35–37). Similarly, it has been 
reported that AMPKα Thr172 phosphorylation was not increased 
following ucOC treatment in C2C12 cells (13). A recent paper 
reported that intraperitoneal injection of osteocalcin increased 
AMPK phosphorylation in mouse muscles during exercise 
(15). Given that AMPK Thr172 phosphorylation is increased in 
skeletal muscle after acute exercise alone, without ucOC (38, 39), 
FigUre 4 | The correlations between the levels of p-ERK2 and the levels of glucose uptake, p-mTOR, p-AKT, and p-AS160. In extensor digitorum longus (EDL)  
and soleus samples, the correlations between the levels p-ERK2 fold-change and the levels of glucose uptake (a,B), p-mTOR fold-change (c,D), p-AKT 
fold-change (e,F), and p-AS160 fold-change (g,h) were analyzed among samples from 30 ng mL−1 undercarboxylated osteocalcin (ucOC) treatment group; 
*P ≤ 0.05 and ***P ≤ 0.001.
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FigUre 5 | The effects of the removal of p-ERK2 enhancement by U0126 on undercarboxylated osteocalcin (ucOC)-stimulated muscle glucose uptake. (a,B) The 
phosphorylation levels, total expression levels, and phospho/total ratio levels of ERK2 in samples treated with dimethyl sulfoxide (DMSO) vehicle, vehicle plus 
30 ng mL−1 ucOC, U0126 (1 μM), and U0126 plus ucOC were assessed in Extensor digitorum longus (EDL) and soleus muscles; (c,D) the glucose uptake of 
samples treated with DMSO vehicle, vehicle plus ucOC (30 ng mL−1), U0126 (1 μM), or U0126 plus ucOC were examined in EDL and soleus muscles. *P ≤ 0.05 and 
**P ≤ 0.01 between paired samples (t-test).
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it is possible that ucOC treatment merely has an additive effect 
on exercise-enhanced phosphorylation of AMPK, but is unable 
to increase its phosphorylation level per  se. However, it should 
be noted that until now no studies have shown ucOC-induced 
change of AMPK phosphorylation over the course of time. Thus, 
a transient increase of AMPK phosphorylation after ucOC treat-
ment still cannot be ruled out.
We neither observed any significant increases in the phos-
phorylation in PKCδ/θ, two important members in novel PKC 
family, in both muscle types (Figure S4 in Supplementary 
Material). This finding suggests a limited role of PKCδ/θ in the 
modulation of muscle glucose uptake by ucOC. However, the 
involvement of other types of PKC in the mechanisms behind this 
ucOC effect is still possible, which warrants further investigation.
We reported that p-AKT in EDL and p-ERK2 in both EDL 
and soleus were enhanced following ucOC treatment with no sig-
nificant changes in phospho/total ratio (Figures 2C and 3A,B). 
This discrepancy may be attributed to an ucOC-induced modest 
increase in total protein expression (Figures 2E and 3D), in addi-
tion to its effect on protein phosphorylation. Consistent with our 
finding, protein synthesis has recently been reported to increase 
in mouse myotubes following 1–2 h of ucOC treatment (40, 41). 
It is possible that ucOC regulates kinase activity by both enhanc-
ing protein phosphorylation, and, to a lesser extent, increasing 
protein abundance.
We report a low positive correlation between p-ERK2 levels 
and p-AKT levels as well as a high positive correlation between 
p-ERK2 levels and p-AS160 levels in EDL, which was consistent 
with our previous findings showing that lower p-ERK levels were 
associated with lower p-AKT levels in rat EDL muscle (30). In 
soleus, p-ERK2 levels were associated with p-AS160 levels, with 
a low positive correlation. As such, we investigated whether the 
removal of ucOC-mediated ERK phosphorylation leads to the 
suppression of the effect of ucOC on skeletal muscles. Pretreatment 
with 1  µM U0126 blocked ucOC-stimulated increases in ERK 
phosphorylation in both muscle types. In EDL, it seems that the 
inhibition of p-ERK2 blocked ucOC-stimulated AKT phospho-
rylation (P =  0.06). Consistently, a previous finding also sug-
gested that partial ERK inhibition dampened ucOC-stimulated 
AKT phosphorylation in C2C12 myotubes (13). In contrast, in 
response to the loss of ucOC-induced ERK phosphorylation, 
ucOC-stimulated glucose uptake and AS160 phosphorylation was 
not compromised. Similarly, in soleus, the inhibition of p-ERK2 
had limited effects on ucOC-stimulated glucose uptake and the 
FigUre 6 | The effects of the removal of p-ERK2 enhancement by U0126 on undercarboxylated osteocalcin (ucOC)-stimulated p-mTOR, p-AKT, and p-AS160. The 
phosphorylation levels, total expression levels, and phospho/total ratio levels of mTOR (a,B), AKT (c,D), and AS160 (e,F) of samples treated with dimethyl sulfoxide 
vehicle, vehicle plus 30 ng mL−1 ucOC, 1 μM U0126, and U0126 plus ucOC were assessed in extensor digitorum longus (EDL) and soleus muscles (N = 5). 
*P ≤ 0.05 and **P ≤ 0.01 between paired samples from the same animal (t-test).
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phosphorylation of signaling proteins. These findings suggest 
that mechanisms underlying ucOC stimulation in skeletal mus-
cle are probably muscle type-specific, but converging at AS160 
phosphorylation, both resulting in the enhancement of glucose 
uptake. The ucOC-stimulated mTOR phosphorylation was also 
not modulated by U0126 pretreatment in both muscle types. 
Thus, whether ERK signaling modulates AKT phosphorylation 
through mTORC2 needs further investigations.
The administration of U0126 as an ERK inhibitor has limita-
tions. One limitation derives from the influence of vehicle DMSO, 
which is widely used as the solvent for U0126. DMSO has been 
shown to exert some impact on skeletal muscle, such as depress-
ing muscle contractility and accelerating muscle injury (42, 43). 
In our study, by comparing the results shown in Figure 2 with 
those in Figure 6, it is suggested that even the presence of a low 
concentration of DMSO (0.1%) may have slightly altered the 
ucOC effect on the phosphorylation of mTOR in EDL and AKT 
in soleus. However, since DMSO was universally added to all sam-
ples in experiments involving the prevention of ucOC-induced 
ERK phosphorylation, the conclusions drawn from comparisons 
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between these samples are unlikely to be affected by DMSO addi-
tion. The other limitation of U0126 administration in this study 
is the capability of U0126 to enhance glucose uptake and AKT 
phosphorylation by itself (44–46). It has been suggested that this 
effect is due to the elevation of AMPK activity that is independent 
of ERK inhibition (47). In the current study, the application of low 
dose (1 μM) of U0126 had a limited effect on AMPK phosphoryla-
tion in both muscle types (Figure S6 in Supplementary Material), 
and glucose uptake and phosphorylation of most other signaling 
proteins were also minimally or not at all affected. Nevertheless, 
other inhibitors or methodologies for ERK inhibition should be 
investigated in future studies to confirm the involvement of ERK 
in the regulation of AKT phosphorylation.
In conclusion, ucOC increases glucose uptake in both glycolytic 
and oxidative muscles in the absence of insulin, via mechanisms 
involving enhanced AS160 phosphorylation. Therefore, ucOC 
should be considered as a potential agent to improve muscle 
glucose uptake in insulin resistant conditions including type 2 
diabetes.
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FigUre s1 | Flow-chart of the protocol used in this study.
FigUre s2 | Blots of all samples in western blot analysis for p-mTOR, p-AKT, 
and p-AS160. Blots of p-mTOR at Ser2481 in Extensor digitorum longus (EDL) 
(a) and soleus (B) samples, p-AKT at Ser473 in EDL (c) and soleus (D) 
samples, and p-AS160 at Thr642 in EDL (e) and soleus (F) samples from 
3 ng mL−1 (N = 10) and 30 ng mL−1 (N = 10) groups are exhibited.
FigUre s3 | Blots of all samples in western blot analysis for p-ERK2 and 
p-AMPKα. Blots of p-ERK2 at Thr202/Tyr204 in Extensor digitorum longus (EDL) 
(a) and soleus (B) samples as well as p-AMPKα at Thr172 in EDL (c) and soleus 
(D) samples from 3 ng mL−1 (N = 9–10) and 30 ng mL−1 (N = 9–10) groups are 
exhibited.
FigUre s4 | The phosphorylation levels of protein kinase C (PKC)δ/θ in 
Extensor digitorum longus and soleus samples treated with Krebs–Henseleit 
buffer buffer control and 30 ng mL−1 ucOC were examined (N = 10).
FigUre s5 | Blots of all samples in western blot analysis for p-ERK2, p-mTOR, 
p-AKT, and p-AS160 in ERK inhibition experiments. Blots of p-ERK2 at Thr202/
Tyr204 in Extensor digitorum longus (EDL) (a) and soleus (B) samples, p-mTOR 
at Ser2481 in EDL (c) and soleus (D) samples, p-AKT at Ser473 in EDL (e) and 
soleus (F) samples, and p-AS160 at Thr642 in EDL (g) and soleus (h) samples 
in ERK inhibition experiments are exhibited (N = 5).
FigUre s6 | The phosphorylation levels of AMPKα at Thr172 in Extensor 
digitorum longus (EDL) and soleus samples treated with treated with dimethyl 
sulfoxide vehicle, vehicle plus 30 ng mL−1 ucOC, 1 μM U0126, and U0126 plus 
ucOC were examined (N = 5).
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